MMPs in human AML subtypes. (A-E) A total of 92 adult patients from the Beat-AML program²⁷  were further categorized on the basis of leukemia-associated genetic driver lesions (red box: MLL-KMT2A subgroup, n = 8; blue box: NPM1-mutated subgroup, n = 32; green box: NPM1–FLT3-mutated subgroup, n = 23; purple box: CBFB-MYH11 subgroup, n = 11; orange box: PML-RARα subgroup, n = 12; yellow box: RUNX1-RUNX1T1 subgroup, n = 6). Transcriptomic data from BM-MNC of 20 healthy individuals (brown box) were selected from the same dataset and included in the analysis for comparison. MMPs’ gene expression levels (A-E) were represented by means of Log2 (FPKM) values. (F) Effect of prinomastat treatment on HL60 human AML cells growth in vitro. Data pooled from 3 independent experiments. (G) Frequency and (H) absolute number of HL60 AML cells and (I) number of overall live cells in the BM of vehicle- and prinomastat-treated NSG mice. Data are shown as mean ± SEM. *P < .05; ns, not significant. P values determined using Student t tests. BM-MNC, bone marrow mononuclear cells.